Categories Earnings, Health Care

Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot

Earnings Update by AlphaStreet

—  Sarepta Therapeutics, Inc.  (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.

— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.

— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.

— SRPT shares ended Wednesday’s regular trading session down 1.14%. 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

360 DigiTech (NASDAQ: QFIN) Q2 2021 Research Summary

The pandemic-induced financial uncertainties have changed the dynamics of the consumer lending market. Customers are being drawn to online lending platforms that provide easy access to credit on convenient terms

Banxa founder Domenic Carosa: Crypto industry seeing huge HNI interest

While bitcoin and other digital currencies have seen a fair share of ups and downs so far this year, investor interest in cryptocurrency has grown undeniably during this period. The

Oracle (ORCL) Q4 earnings, revenue beat Street view

Software giant Oracle Corporation (NYSE: ORCL) reported a 28% growth in fourth-quarter earnings, aided by an increase in revenues. The results also topped Wall Street's prediction. At $11.2 billion, revenues

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top